Ind-Swift's Q3 Financial Results Show Decline

Ind-Swift, a microcap pharmaceutical company, has recently declared its financial results for the quarter ended September 2023. The company's net sales for the quarter have shown a decline of -21.96% compared to the previous quarter, while the consolidated net profit has seen a significant decrease of -553.81%. The operating profit (PBDIT) excluding other income has also shown a decline of -39.46% in the same period.

The company's interest expenses have increased by 22.14% in the quarter, indicating a rise in borrowings. The operating profit margin (excluding other income) has also fallen compared to the previous quarter. These financial results have led to a negative score of -6 for Ind-Swift, a significant decrease from the score of 11 in the last three months.

However, there are some positive aspects to the company's performance. The net sales for the half-yearly period have shown a growth of 33.24% year on year, indicating a positive sales trend. But, the profit before tax (PBT) less other income and the profit after tax (PAT) have both shown a significant decline compared to the average of the previous four quarters. The company's earnings per share (EPS) have also decreased, indicating a decline in profitability.

Overall, Ind-Swift's financial performance for the quarter ended September 2023 has been negative. The company's stock has been given a 'Strong Sell' call by MarketsMOJO, and the near-term trends for PBT and PAT are also negative. Investors should carefully consider these financial results before making any investment decisions.